CRISPR-Cas9 for cancer therapy: Opportunities and challenges. (10th April 2019)

• Record Type: Journal Article
• Authors: Chen, Minjiang; Mao, Aiwu; Xu, Min; Weng, Qiaoyou; Mao, Jianting; Ji, Jiansong
• Is Part Of: Cancer letters. Volume 447(2019)
• Page Start: 48
• Page End: 55
• Publication Date: 2019-04-10
• Subjects: CRISPR-Cas9 -- Cancer -- Gene editing -- Immunotherapy -- Oncolytic virotherapy; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.canlet.2019.01.017
• Languages: English
• ISSNs: 0304-3835

Abstract

Abstract: Cancer is a genetic disease stemming from cumulative genetic/epigenetic aberrations. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas9-mediated genome editing technology has been extensively applied in various cell types and organisms, both in vitro and in vivo, for efficient gene disruption and gene modification. CRISPR-Cas9 has shown great promise for the treatment of cancer. However, despite its advantages and tremendous potential, numerous challenges, such as fitness of edited cells, editing efficiency, delivery methods and potential off-target effects, remain to be solved for completely clinical application. Here, we present the potential applications and recent advances of CRISPR-Cas9 in cancer therapy, and discuss the challenges that might be encountered in clinical applications. Highlights: CRISPR-Cas9 has been applied in various cell types and organisms for efficient gene disruption and gene modification. Despite the potential of CRISPR-Cas9 in cancer treatment, some challenges remain to be solved for clinical application. The continuous advances in CRISPR-Cas9 will increase safety and effectivity of therapy for patients with cancer.